GRO Biosciences develops a synthetic biology platform that provides access to non-standard amino acids (NSAAs) for therapeutic applications.

GRO Biosciences

IPhone / Mobile Compatible

Viewport Meta

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

WordPress

Global Site Tag

Font Awesome

Mobile Non Scaleable Content

Co-Founder and CEO

Dan Mandell

Associate Director, Application Sciences

Bijou Bose

Biotechnology Project Manager

Karen Bui

Sales and Support

Scott Frankenthaler

Engineering

Anushka Saha

Chief Scientific Officer

Christopher Gregg

Dana Braff

Derek Clay

Chief Business Officer

Edward Stewart

J. Marisha Collins

Kevin Bitterman

Dan Becker

Geoffrey W. Smith

Lucio Iannone

Bruce Beutel

Daniel J. Mandell

Co-Founder and Chief Executive Officer

Ross Thyer

Co-Founder and Scientific Advisor

Chief Science Officer, Co-Founder, Director

Justin Feng

Principal Scientist

Edward J. Stewart

Tracey Lodie

Chief Development Officer

Benjamin Stranges

Marc Lajoie

Co-Founder and Advisor

United States Medical Companies with Early Stage Venture Funding

Companies With Fewer Than 100 Employees (Top 10K)

Companies With Less Than $1M in Revenue (Top 10K)

Therapeutics Companies with Early Stage Venture Funding

GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. 

GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity.

Access Biotechnology

Atlas Venture

Series B - GRO Biosciences

Leaps by Bayer

Redmile Group

Series A - GRO Biosciences

National Science Foundation

Grant - GRO Biosciences

Digitalis Ventures

Seed Round - GRO Biosciences

Boston

Massachusetts

United States

North America

GRO Biosciences Closes $60M Series B

GRO Biosciences Closes $60.3M Series B Financing

GRObio Secures $60.3 Million in Series B Financing to Advance Protein Therapeutics

GRO Biosciences closes $60 million Series B financing

GRO Bio gathers $60M series B to take gout rival to Krystexxa into clinic

George Church spinout to enter clinic with new $60M investment

GRO Biosciences: Protein Therapeutics Company Raises $60 Million In Series B

GRO Biosciences Closes $60M Series B Financing Co-Led by Atlas Venture and Access Biotechnology

India

Asia

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Oct 24, 2024 5:05 PM	41db365d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general	Oct 24, 2024 5:05 PM	b810aae5
news processing advanced	general
crunchbase trigger	general	Oct 28, 2024 1:50 PM	c7fdb93c
crunchbase profile	general	Oct 29, 2024 9:01 AM	6655fda0
li profile	general
translate crunchbase fundingrounds	general
peers	general	Oct 24, 2024 5:05 PM	2d4f3b7e
news basic	general	Oct 24, 2024 5:05 PM	1ed09c94
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis	Oct 24, 2024 5:05 PM	0a3e77cb
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

GROB

COM:GROBIO

GRO Biosciences